Syn-AKE Molecular Structure & Chemical Properties

Syn-AKE represents a pioneering achievement in biomimetic peptide design, synthesized to replicate the neuromuscular activity of Waglerin-1, a naturally occurring peptide isolated from the venom of the Temple Viper (Tropidolaemus wagleri). First synthesized in 2004 and patented by Pentapharm Ltd. (Switzerland) in 2006, this synthetic tripeptide has become one of the most extensively studied topical anti-aging peptides in dermatological research. Unlike traditional anti-aging compounds that require invasive administration, Syn-AKE’s low molecular weight (less than 500 Da) enables effective topical penetration through the stratum corneum, making it particularly valuable for non-invasive cosmetic research applications. The peptide’s structural optimization captures only the essential amino acid sequence responsible for neuromuscular receptor activity while eliminating the toxic components of the full venom peptide.

Chemical Structure

[IMAGE PLACEHOLDER] Insert 2D chemical structure image here Image URL: https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?cid=71465152&t=l Alt text: Syn-AKE dipeptide diaminobutyroyl benzylamide diacetate molecular structure Source credit: PubChem Position: Center-aligned below heading

2D molecular structure (Source: PubChem)

Technical Specifications

The tripeptide structure consists of beta-alanine, proline, and diaminobutyric acid with a benzyl amide terminus, creating a biomimetic configuration that selectively targets nicotinic acetylcholine receptors while maintaining excellent topical bioavailability compared to larger peptide structures.

Syn-AKE Mechanism of Action

Syn-AKE exerts its biological effects through selective antagonism of muscular nicotinic acetylcholine receptors (mnAChR) at the neuromuscular junction, mimicking the mechanism of Waglerin-1 but in a controlled, reversible manner. Research suggests the peptide functions as a competitive antagonist that temporarily blocks receptor activation without producing permanent changes, distinguishing it from irreversible neuromuscular blockers.

Primary Cellular Pathways

Nicotinic Acetylcholine Receptor Antagonism – Neuromuscular Blockade

The primary mechanism of Syn-AKE involves binding to the epsilon subunit of muscular nicotinic acetylcholine receptors (mnAChR), preventing acetylcholine from binding and initiating muscle contraction[1]. This receptor interaction creates:

• Reversible blockade of ion channel opening, preventing sodium ion uptake
• Reduced frequency of muscle cell excitation and contraction
• Temporary relaxation of superficial facial muscles
• Decreased formation of dynamic expression lines

In vitro studies using cultured muscle cells demonstrated that 0.025% Syn-AKE reduced muscle contraction frequency by 36% after one minute and 82% after two hours, indicating rapid onset with sustained activity[2].

SIRT1 Receptor Binding – Anti-Aging Signaling

Recent molecular docking studies revealed that Syn-AKE demonstrates strong binding affinity to Sirtuin 1 (SIRT1) receptors with a docking score of -9.32 kcal/mol, suggesting additional mechanisms beyond neuromuscular activity[3]. This interaction involves:

• Multiple hydrogen bond formations with ASP-111, VAL-175, and HIS-126 residues
• Salt bridge and pi-pi stacking interactions supporting binding stability
• Potential activation of cellular anti-aging pathways independent of muscle effects
• Antioxidant activity through SIRT1-mediated cellular protection mechanisms

This dual mechanism suggests Syn-AKE may influence both immediate muscle activity and longer-term cellular aging processes.

Matrix Metalloproteinase Modulation – Extracellular Matrix Protection

Computational modeling studies indicate Syn-AKE interacts with matrix metalloproteinases (MMPs), specifically MMP-1, MMP-8, and MMP-13, which are key enzymes in collagen degradation[3]. Key findings include:

• Binding affinity ranking: MMP-13 > MMP-8 > MMP-1
• Potential inhibition of collagen breakdown in dermal tissue
• Protection of extracellular matrix structure during muscle relaxation
• Support for dermal integrity alongside wrinkle-smoothing effects

Antioxidant Activity – Free Radical Scavenging

Laboratory investigations using DPPH free radical assays demonstrated concentration-dependent antioxidant activity of Syn-AKE[3]. This mechanism contributes to:

• Direct scavenging of reactive oxygen species
• Protection against oxidative stress-induced aging
• Complementary protection of skin cells during topical application
• Potential enhancement of overall dermal health beyond mechanical effects

Sodium Channel Modulation – Cellular Excitability

By blocking acetylcholine receptors, Syn-AKE prevents the opening of voltage-gated sodium channels in muscle cell membranes[4]. This results in:

• Maintained closed state of ion channels
• Prevention of sodium ion influx required for action potential propagation
• Reduced cellular excitability in target muscle fibers
• Localized effect without systemic neuromuscular impact

Syn-AKE Research Applications & Key Findings

Dermatological and Topical Research

Wrinkle Reduction and Skin Smoothing Studies

The most extensively studied application of Syn-AKE involves its effects on facial expression lines and wrinkle depth in topical formulations. A clinical study involving 50 human subjects using 4% Syn-AKE topically twice daily for 28 days demonstrated[5]:

• Wrinkle depth reduction of up to 52% on forehead expression lines
• Smoothing effect measurable in 80% of participants
• Wrinkle reduction evident in 73% of subjects
• Superior efficacy compared to acetyl hexapeptide-8 (Argireline) in head-to-head comparison

Skin surface measurement studies using profilometry showed improvements in skin roughness parameters (Ra, Rz, and Rt measurements), with effects visible as early as 1-2 hours post-application continuing through 28 days of use[5].

Muscle Contraction Frequency Research

In vitro cellular studies using cultured muscle cells examined Syn-AKE’s direct effects on contractile activity[2]:

• 71% reduction in muscle contractions within 1 minute of 0.025% peptide application
• 58% reduction maintained after 2 hours of exposure
• Dose-dependent response with optimal activity at 0.5-4% concentrations
• Reversible effects upon peptide removal without permanent muscle changes

These findings established the rapid-onset, sustained-duration profile that characterizes Syn-AKE’s neuromuscular effects.

Comparative Anti-Aging Peptide Research

Studies comparing Syn-AKE with other “Botox-like” peptides provided context for its relative efficacy[6]:

• More effective than acetyl hexapeptide-8 (Argireline) in reducing forehead lines (24.62% combined effect vs. 16.26% for Argireline alone)
• Synergistic effects observed when combined with leuphasyl in dual-peptide formulations
• Non-inferior to pentapeptide-3 (Vialox) in smoothing expression lines
• Faster onset of visible effects compared to other topical neuromuscular peptides

Molecular Interaction and Receptor Binding Studies

Computational Docking and Dynamics Research

Advanced in silico studies examined Syn-AKE’s binding characteristics to multiple biological targets[3]:

• SIRT1 binding demonstrated highest affinity (-9.32 kcal/mol) among tested targets
• Stable binding maintained through 50 nanosecond molecular dynamics simulations
• Multiple interaction types (hydrogen bonds, salt bridges, pi-stacking) contribute to stability
• Binding pocket residues identified for potential structure-activity optimization

Safety and Cytotoxicity Research

Laboratory safety profiling using standard assays established preliminary safety parameters[3]:

• MTT cytotoxicity assays determined safe concentration ranges for topical formulations
• Ames genotoxicity testing showed no mutagenic activity at cosmetic use concentrations
• No sensitization or irritation reported in manufacturer testing (limited independent validation)
• Some anecdotal reports of skin reactions (redness, itching) in sensitive individuals

Formulation and Penetration Research

Studies examining topical delivery characteristics revealed[7]:

• Molecular weight below 500 Da threshold enables effective stratum corneum penetration
• Compatible with serum, cream, gel, and emulsion formulation bases
• Maintains stability in pH range 3.0-5.5 typical of cosmetic formulations
• Optimal use concentrations identified as 0.5-4% for topical applications

Syn-AKE Pharmacokinetics & Metabolism

Absorption & Distribution

Syn-AKE exhibits favorable topical absorption characteristics due to its relatively low molecular weight and lipophilic properties. Following topical application in formulation studies:

• Dermal penetration occurs within minutes of application, with activity detectable at target sites within 1-2 hours
• Small molecular size (495.58 Da) facilitates passage through stratum corneum barrier
• Localized concentration at application sites without significant systemic absorption
• Distribution pattern suggests targeting of superficial dermal layers and neuromuscular junctions

The peptide’s topical bioavailability distinguishes it from larger peptides that typically require injection for biological activity. However, quantitative pharmacokinetic parameters (Cmax, Tmax, AUC) for topical Syn-AKE have not been extensively characterized in published literature.

Metabolism & Elimination

The metabolic fate of Syn-AKE remains incompletely characterized, though general peptide degradation pathways likely apply:

• Enzymatic degradation through peptidases in skin tissue and systemic circulation
• Rapid clearance expected based on small peptide structure
• Half-life estimates not well-established in human studies
• Minimal systemic accumulation expected with topical application

A notable characteristic is the duration-potency disconnect: despite presumed rapid peptide degradation, effects on muscle contractility persist for hours after single applications and cumulative effects develop over weeks, suggesting either tissue retention, formation of active metabolites, or triggering of persistent signaling cascades.

Excretion Pathways

Limited data exists on specific excretion pathways for topically applied Syn-AKE:

• Degradation products likely eliminated through normal peptide metabolic pathways
• Renal clearance probable for any systemically absorbed peptide or fragments
• No accumulation detected in repeated-use studies (manufacturer data)
• Excretion kinetics require further investigation through labeled peptide studies

The reversible nature of Syn-AKE’s effects and absence of reported accumulation issues suggest efficient clearance mechanisms, though detailed elimination studies are lacking in peer-reviewed literature.

Syn-AKE Research Protocols & Administration

Concentration Ranges in Published Research

Topical research investigations have employed various Syn-AKE concentrations depending on formulation type and study design:

• Human topical studies: 4% concentration most commonly studied (optimal efficacy observed)
• In vitro muscle cell studies: 0.025% demonstrated significant contractility reduction
• Formulation research: 0.5-4% range identified as effective and well-tolerated
• Comparative studies: 5% concentration used in some peptide comparison trials

Important: These are concentrations used in topical dermatological research formulations and cannot be directly applied to other delivery routes or species due to significant differences in skin permeability, receptor distribution, metabolic activity, and tissue-specific sensitivity. Topical absorption varies dramatically across species and anatomical sites.

Administration Routes in Research

Syn-AKE has been investigated exclusively through topical application routes:

• Topical cream formulations – Most common delivery method in human studies; twice-daily application
• Serum formulations – Used in facial anti-aging research; higher peptide concentrations possible
• Gel formulations – Studied for localized application to specific wrinkle sites
• Emulsion bases – Research on cosmetic formulation optimization and stability
• Direct topical powder – Available in research-grade form for formulation development

Note: Unlike Botox and some other neuromuscular agents, Syn-AKE is designed specifically for topical application and has not been studied via injection routes. This topical-only approach limits systemic exposure and off-target effects.

Application Protocols in Research

Standard research protocols for Syn-AKE topical studies typically include:

• Application frequency: Twice daily (morning and evening) in most efficacy studies
• Treatment duration: 28 days minimum for measurable wrinkle reduction; up to 6 months in some trials
• Target areas: Forehead lines, crow’s feet, periorbital region, nasolabial folds
• Formulation compatibility: Combined with other peptides (Syn-Coll, Matrixyl 3000, Argireline) for synergistic research
• Assessment methods: Profilometry, photographic analysis, subject self-assessment scales

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite two decades of research since its synthesis in 2004, Syn-AKE faces significant evidence gaps that limit comprehensive understanding of its safety and efficacy profile.

Limited Human Clinical Data

The most significant limitation is the scarcity of rigorous, peer-reviewed human clinical trials:

• Few independent clinical trials published in peer-reviewed scientific journals
• Most efficacy data derived from manufacturer-sponsored studies or in silico modeling
• No large-scale, multi-center clinical trials examining long-term outcomes
• Limited data on optimal concentration, application frequency, and treatment duration
• Demographic diversity of studied populations not well-characterized

The primary human efficacy data comes from a 50-subject study and various smaller manufacturer trials, representing a narrow evidence base for such a widely used cosmetic ingredient.

Mechanistic Understanding Gaps

Fundamental aspects of Syn-AKE’s mechanism remain incompletely understood:

• Precise receptor binding site on mnAChR epsilon subunit not crystallographically confirmed
• Relative contribution of SIRT1 binding versus neuromuscular effects unclear
• Whether MMP inhibition occurs at physiologically relevant concentrations uncertain
• Skin penetration depth and target tissue concentrations not quantified in vivo
• Duration of receptor occupancy and reversibility kinetics inadequately characterized

Long-Term Safety Considerations

Critical safety questions remain unanswered despite widespread cosmetic use:

• Chronic use effects beyond 6 months not systematically studied
• Potential for localized muscle atrophy with extended application unknown
• Systemic absorption and off-target neuromuscular effects not rigorously assessed
• Pregnancy and lactation safety completely unstudied
• Interaction potential with other topical or systemic medications uncharacterized
• Sensitization and allergic reaction incidence not well-documented in large populations

Regulatory & Competitive Sport Status

FDA Position

Syn-AKE occupies an ambiguous regulatory position:

• Classified as a cosmetic ingredient when used in topical formulations, not as a drug
• Not subject to FDA pre-market approval for cosmetic applications
• No therapeutic claims permitted for anti-wrinkle or anti-aging benefits
• Generally Recognized as Safe (GRAS) status not established
• Subject to cosmetic ingredient safety standards but not drug efficacy requirements

The FDA does not regulate cosmetic peptides with the same rigor as pharmaceutical agents, meaning safety and efficacy standards are less stringent than for prescription medications.

WADA Prohibition

Syn-AKE is not currently listed on the World Anti-Doping Agency (WADA) Prohibited List:

• Not prohibited for competitive athletes in topical cosmetic applications
• No known ergogenic or performance-enhancing effects relevant to sport
• Neuromuscular effects are localized and cosmetic rather than systemic
• No detection methods or testing protocols established

Cosmetic Ingredient Review Status

The Cosmetic Ingredient Review (CIR) Expert Panel has not formally evaluated Syn-AKE:

• No independent CIR safety assessment published as of current date
• Safety profile based primarily on manufacturer data
• Anecdotal reports of skin reactions (swelling, redness, itching, stinging) in some users
• Recommended patch testing before widespread facial application

Research Classification: Syn-AKE is available as a cosmetic ingredient for formulation research and topical product development. It is intended for external use only in cosmetic formulations. This peptide is not approved for pharmaceutical use, injection, or medical applications. All research applications should follow appropriate cosmetic safety testing protocols and good manufacturing practices.

References

1. Balaev, A.N., Okhmanovich, K.A., & Osipov, V.N. (2014). A shortened, protecting group free, synthesis of the anti-wrinkle venom analogue Syn-Ake exploiting an optimized Hofmann-type rearrangement. Tetrahedron Letters, 55(42), 5745-5747.
2. Pentapharm Ltd. Technical Documentation. (2006). SYN-AKE: Synthetic tri-peptide for anti-wrinkle applications. Company technical bulletin.
3. Mortazavi, H., & Nikmanesh, B. (2023). Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests. Journal of Biomolecular Structure and Dynamics, 42(10), 5233-5246. PubMed
   
4. Molles, B.E., Rezai, P., Kline, E.F., McArdle, J.J., Sine, S.M., & Taylor, P. (2002). Identification of residues at the alpha and epsilon subunit interfaces mediating species selectivity of Waglerin-1 for nicotinic acetylcholine receptors. Journal of Biological Chemistry, 277(7), 5433-5440. PubMed
   
5. DSM-Firmenich Clinical Study Data. (2009). Efficacy and safety of SYN-AKE 4% in reducing expression lines. Internal clinical report referenced in International Journal of Cosmetic Science review.
6. Gorouhi, F., & Maibach, H.I. (2009). Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science, 31(5), 327-345. PubMed
   
7. Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 19(7), 1987. PubMed
   
8. Lupo, M.P., & Cole, A.L. (2007). Cosmeceutical peptides. Dermatologic Therapy, 20(5), 343-349. PubMed
   
9. Schmidt, J.J., & Weinstein, S.A. (1995). Structure-function studies of waglerin I, a lethal peptide from the venom of Wagler’s pit viper, Trimeresurus wagleri. Toxicon, 33(9), 1043-1049. PubMed
   
10. McArdle, J.J., Angaut-Petit, D., Mallart, A., Bournaud, R., Faille, L., & Brigant, J.L. (1999). Advantages of the triangularis sterni muscle of the mouse for investigations of synaptic phenomena. Journal of Neuroscience Methods, 88(2), 189-196. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. Syn-AKE is intended for topical cosmetic formulation research and development use only.